On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

Zealand Pharma (Denmark)

InstitutionResearch output, impact & collaborations

Zealand Pharma (Denmark) is a institution indexed in ScholarIQ from OpenAlex.

What is known about Zealand Pharma (Denmark)?

ScholarIQrecord summary

Zealand Pharma (Denmark) is a research organisation in Copenhagen, DK. OpenAlex records 354 works and 26,665 citations for it. 137 researchers list it as their most recent affiliation.

How many works does Zealand Pharma (Denmark) have?

ScholarIQindexed works

Zealand Pharma (Denmark) has 354 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Zealand Pharma (Denmark) →

How many citations does Zealand Pharma (Denmark) have?

ScholarIQcitation count

Zealand Pharma (Denmark) has 26,665 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for Zealand Pharma (Denmark) →

How many researchers are at Zealand Pharma (Denmark)?

ScholarIQresearcher count

Zealand Pharma (Denmark) has 137 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at Zealand Pharma (Denmark)?

ScholarIQavg h-index

Zealand Pharma (Denmark) has an average h-index of 44.5 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Zealand Pharma (Denmark)?

ScholarIQror

The ROR for Zealand Pharma (Denmark) is on the source record.

Open the ROR →

What is the OpenAlex record for Zealand Pharma (Denmark)?

ScholarIQopenalex

The OpenAlex for Zealand Pharma (Denmark) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Zealand Pharma (Denmark)?

ScholarIQtop researchers by citations

Martijn van de Bunt · Pancreatic function and diabetes

118 works16,149 citations

David M. Kendall · Diabetes Management and Research

153 works10,035 citations

What are the most-cited papers on Zealand Pharma (Denmark)?

ScholarIQmost cited works

Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea

David M. Kendall, Matthew C. Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis Dong Hwan Kim, Mark Fineman, Alain Baron

Diabetes Care. 20051,180 CitationsOPEN ACCESS

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Daniel J. Drucker, John B. Buse, Kristin Taylor, David M. Kendall, Michael Trautmann, Dongliang Zhuang, Lisa A. Porter

The Lancet. 20081,070 Citations

A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

Ronald Goldberg, David M. Kendall, Mark A. Deeg, John B. Buse, Anthony J. Zagar, Jane Pinaire, Meng H. Tan, Mehmood Khan, Alfonso T. Perez, Scott J. Jacober, for the GLAI Study Investigators

Diabetes Care. 2005795 CitationsOPEN ACCESS

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

Lawrence Blonde, E. Klein, J. Han, B. Zhang, Susanna Mac, Terri Poon, Kristin Taylor, Michael Trautmann, D. D. Kim, David M. Kendall

Diabetes Obesity and Metabolism. 2006419 CitationsOPEN ACCESS

Recommendations for Management of Diabetes During Ramadan

Monira Alarouj, Samir H. Assaad‐Khalil, John B. Buse, Ibtihal Fahdil, Mohamed A. H. Fahmy, Sherif Hafez, Mohamed Hassanein, Mahmoud Ibrahim, David M. Kendall, Suhail Kishawi, Abdulrazzaq Al-Madani, Abdullah Ben Nakhi, Khaled Tayeb, Abraham Thomas

Diabetes Care. 2010410 CitationsOPEN ACCESS

How much of the research on Zealand Pharma (Denmark) is open access?

ScholarIQopen access share

82%OPEN ACCESS

Gold

Green

Hybrid

18%

Bronze

55%

Closed

18%